Suppr超能文献

新型吡唑基 2-氨基嘧啶衍生物作为 HSP90 抑制剂的设计、合成及分子对接研究。

Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.

机构信息

Department of Pharmaceutical Chemistry, Gokaraju Rangaraju College of Pharmacy, Kukatpally, Hyderabad, India.

Department of Pharmacology, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, India.

出版信息

Arch Pharm (Weinheim). 2019 Oct;352(10):e1900063. doi: 10.1002/ardp.201900063. Epub 2019 Aug 14.

Abstract

A series of novel pyrazolyl 2-aminopyrimidine derivatives (7a-t) were designed based on scaffold hopping techniques, synthesized and biologically evaluated for their HSP90 inhibition and anticancer activity. Several compounds exhibited potent HSP90 inhibition with IC values less than that of the reference standard 17-AAG (1.25 µM). The most potent compound 7t displayed excellent HSP90 inhibition with an IC of 20 nM and in vitro antiproliferative potential against three cancer cell lines (IC  < 5 µM). 7t also induced dose dependent degradation of client proteins (pHER2 and pERK1/2) in Western blot analysis. Several structural features of 7p-t oriented the molecules to retain all the essential binding interactions with HSP90, as observed by rationalized docking studies. Therefore, the para-nitrophenyl ring on the central pyrazole ring along with the 2-amino group on the pyrimidine ring are the crucial features in the development of novel HSP90 inhibitors based on this scaffold for targeted anticancer therapy.

摘要

基于构象跳跃技术,设计了一系列新型吡唑基 2-氨基嘧啶衍生物(7a-t),并对其 HSP90 抑制和抗癌活性进行了合成和生物评价。几种化合物表现出较强的 HSP90 抑制活性,IC 值均小于参考标准 17-AAG(1.25 μM)。最有效的化合物 7t 对 HSP90 的抑制活性非常强,IC 为 20 nM,对三种癌细胞系的体外增殖潜力(IC < 5 μM)。7t 还在 Western blot 分析中诱导了剂量依赖性的客户蛋白(pHER2 和 pERK1/2)降解。通过合理化对接研究观察到,7p-t 的几个结构特征使分子保留了与 HSP90 的所有必需结合相互作用。因此,在基于该支架开发新型 HSP90 抑制剂以进行靶向抗癌治疗时,中央吡唑环上的对硝基苯基环和嘧啶环上的 2-氨基是关键特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验